Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18
Joined March 2012
- Tweets 820
- Following 1,107
- Followers 1,061
- Likes 2,061
220 Photos and videos
Impressive data with mRNA personalised vaccine seen here in patients with melanoma.
Trials in lung cancer open and recruiting (open at SBH) and we look forward to see outcome data!
#ASCO26
Jun 1
Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
ascopubs.org/doi/10.1200/JCO…
120
Dr Adam Januszewski retweeted
#ASCO26 With neoadjuvant lorlatinib, pCR 47% and MPR 81%. Amazing. RR 84% and 1y EFS 97%. Down staging of nodes in 90%. Very reassuring and consistency safety results. Phenomenal clinical results.
2
27
55
12,802
Great to see @AlfredSo12 presenting UK-wide data on behalf of @onctrainees @ASCO on time of day data in patients with NSCLC receiving IO.
#ASCO2026
1
2
4
330
Presented at #ASCO26:
Among patients with 𝘙𝘌𝘛 fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. Full phase 3 LIBRETTO-432 trial results: nej.md/3Q3QcIo
@ASCO
ALT Graph depicting survival rates over time for patients using selpercatinib versus a placebo in early-stage RET fusion-positive non-small-cell lung cancer. The x-axis shows months since randomization, and the y-axis represents the percentage of patients. The logo for the New England Journal of Medicine is present.
71
232
25,689
Dr Adam Januszewski retweeted
May 31
🔥🔥🔥Perhaps the most remarkable aspect of LIBRETTO-432 is not the hazard ratio.
It’s how far the field has come.
A decade ago, RET fusions were largely undruggable. Today, a highly selective RET inhibitor reduces the risk of recurrence or death by nearly 83% in patients treated with curative intent.
From an orphan alteration to one of the biggest success stories in precision oncology.
#ASCO26
@OncoAlert @OncoReporte @MedwatchKate @Larvol
@WeOncologists
@GlopesMd
@StephenVLiu
@peters_solange
@CharuAggarwalMD
@MartinReck2
@christine_lovly
@DrSanjayPopat
@DrMirallas
@FernandoOnco
@bmassutis @UmbertoMalapel1
@jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo
@Latinamd @JulienMazieres @TerriConneran @BRicciutiMD @LungCancerEu
19
32
2,590
Dr Adam Januszewski retweeted
May 29
PAPILLON (amivantamab chemotherapy) our current standard for EGFRex20 NSCLC: PFS 11.4m with PFS HR 0.40 and RR 73%. Sunvozertinib appealing oral option with different toxicity. As of now, though, sunvozertinib still not commercially available in US...
nejm.org/doi/full/10.1056/NE…
2
11
23
1,474
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
52
2,054
5,578
2,466,048
🚨Great data with doubling of OS with HR of 0,4 in pancreatic cancer with KRAS mutations with use of Daraxonrasib
Standing ovation.
We look forward to the phase 3 vs docetaxel in lung cancer with KRAS mutations (open with us at SBH)
#ASCO2026
1
140
Dr Adam Januszewski retweeted
May 31
May 26
Delighted to present our NOTCH study on time-of-day Rx in aNSCLC PDL1≥50% at ASCO 2026.
Very excited for my first ASCO congress in person and looking forward to it. Please drop by to say hi at the lung cancer poster session on Sunday morning!
#ASCO26 #LCSM @onctrainees
1
1
135
Dr Adam Januszewski retweeted
May 29
#ASCO26
“Atypical” EGFR mutations are no longer an afterthought in NSCLC.
We’re finally seeing dedicated prospective data instead of small retrospective series.
Key signals:
🟢 Afatinib: early benchmark activity
🟢 Osimertinib: CNS-friendly option
🟢 Furmonertinib: ORR up to 68%
🟢 Amivantamab lazertinib: promising durability with mPFS nearing 20 months in 1L
Most exciting update:
🧬 ALPACCA is now the first randomized phase III trial dedicated to PACC atypical EGFR mutations.
After years of lumping these patients together, precision treatment for uncommon EGFR is finally becoming real.
#OncoTwitter #MedTwitter #LungCancer @OncoAlert @myesmo @esmo_open @ASCO @larvol
21
39
2,587
Dr Adam Januszewski retweeted
Where is the ethical justification for offering pembrolizumab alone to patients with low PD-L1 expression in this trial? What would these patients receive if they were not participating in the study? Chemotherapy alone? Thats why patients participate? To take the chance to be assigned to the experimental arm? Unfortunately a randomized phase 3 trial with no clinical implications due to a flawed trial design. #ASCO26 #LCSM
May 29
Presented at #ASCO26—OptiTROP-Lung05 phase 3 interim analysis.
The findings suggest first-line treatment with sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly prolonged PFS vs pembrolizumab alone in patients with PD-L1-positive advanced NSCLC without targetable genomic alterations.
Read more: spkl.io/601976v7P
ALT Figure: Progression-free survival as assessed by blinded independent central review.\n\n(A) Kaplan\u2013Meier estimates of progression-free survival as assessed by blinded independent central review. (B) Forest plot of progression-free survival in subgroups. One patient with thymoma was excluded from the pembrolizumab group in the subgroup analysis of histologic type. Subgroup analyses will not be presented for any subgroup variable in which one or more levels account for less than 10% of the total analysis population. Confidence intervals have not been adjusted for multiplicity and should not be used to infer statistical significance. Sac-TMT=sacituzumab tirumotecan. PD-L1=programmed death ligand 1. TPS=tumour proportion score. NR=not reached. NE=not estimable.
7
26
131
21,515
Dr Adam Januszewski retweeted
May 30
1stL in KRASG12Cmut NSCLC will be crowded and complex. Elisrasib, another KRASG12Coff inh, reported activityn in 1stL alone and combo with pembro. Next future: how to decide intensification? Based on PDL1, comut, brain met status🤯.Will not be easy!! To icity is a concern #ASCO26
37
71
3,668
Dr Adam Januszewski retweeted
May 30
Dr. @peters_solange with phase II results from ROSETTA Lung-02 #ASCO26: global study of 1L pumitamig (PD-L1 / F VEGF-A bispecific antibody) plus chemo in NSCLC. Preclinically, pumitamig an effective PD-L1 and VEGF-A antagonist and forms complexes that lead to internalization.
2
36
73
4,970
Dr Adam Januszewski retweeted
May 30
Dr. @FSkoulidis #ASCO26: Krascendo 170 - first-line divarasib pembrolizumab in KRAS G12C NSCLC. In PDL1 , RR 73%, mPFS 19.3m! In PDL1-, unconfirmed RR 70%. Impressive efficacy and DCR.
2
39
103
10,154
Sac-TMT with pembro vs pembro along with aNSCLC
Impressive results of first line ADC in combination with pembro.
Although pembro single agent not SOC in PDL1 low
#ASCO2026
126
7 year follow up for front line lotlatinib in metastatic ALK re-arranged lung cancer.
Our best drug in lung cancer … ever?
And with no difference in outcomes with dose reduction
#ASCO2026
101
Dr Adam Januszewski retweeted
May 26
Delighted to present our NOTCH study on time-of-day Rx in aNSCLC PDL1≥50% at ASCO 2026.
Very excited for my first ASCO congress in person and looking forward to it. Please drop by to say hi at the lung cancer poster session on Sunday morning!
#ASCO26 #LCSM @onctrainees
1
2
5
663
Dr Adam Januszewski retweeted
May 18
🫁 Izalontamab brengitecan in actionable NSCLC.
Phase Ib iza-bren showed activity across actionable NSCLC alterations beyond classical EGFR mutations:
• ORR 39.7%, DCR 85.9%, median PFS 7.0 mo
• EGFR exon20ins/nonclassical EGFR: ORR 69.2%, PFS 10.5 mo
• HER2-mutant: ORR 52.9%, PFS 7.5 mo
Relevant hematologic toxicity, but manageable safety profile overall.
📖 @JCO_ASCO
DOI 👉🏻 doi.org/10.1200/JCO-25-01929
#CánCare #NSCLC #EGFR #HER2 #ADC #targetedtherapy
3
10
23
2,493
Dr Adam Januszewski retweeted
May 1
Pleased that our case report on the rarely described EUS-guided transoesophageal pericardiocentesis for NSCLC posterior pericardial effusion has been published in Cardio-Oncology: rdcu.be/fgqPT
@AdamJanuszewski @medicine98 @tb_doc @dr_manisty
1
2
2
324
🚨 Check out this new report discussing how can we provide fairer access to cancer treatments in collaboration with @macmillancancer
⬇️
publicpolicyprojects.com/no-…
2
3
225